Isoliquiritigenin attenuates doxorubicin-induced cardiomyopathy by alleviating mitochondrial dysfunction and oxidative damage through the Piezo1/Ca²⁺/Pdk4 signaling axis.
BACKGROUND Doxorubicin (DOX) is widely employed as an antineoplastic agent in clinical settings, yet its therapeutic utility is constrained by dose-dependent cardiotoxicity, partly resulting from oxidative injury to cardiomyocytes and impairment of mitochondrial function. Hence, there is an urgent imperative to develop...